SCHEMBL16014748

SCHEMBL16014748

Brc1ncn(Cc2ccccc2)n1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 5/20 0.58
HDAC6 Q9UBN7 5/20 0.58
CYP19A1 P11511 6/20 0.47
CYP11B1 P15538 2/20 0.41
CYP11B2 P19099 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
TNF P01375 1/20 0.41
CYP1A2 P05177 1/20 0.39
POLB P06746 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
MAPT P10636 1/20 0.39
TBXAS1 P24557 1/20 0.39
QPCT Q16769 1/20 0.39
CYP4Z1 Q86W10 1/20 0.39
QPCTL Q9NXS2 1/20 0.39
ALDH1A1 P00352 2/20 0.38
KDM4E B2RXH2 1/20 0.38
NPC1 O15118 1/20 0.38
LMNA P02545 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25416318 0.78 CYP19A1 (0.48) HDAC1HDAC6CYP19A1CYP11B1CYP11B2
SCHEMBL16014518 0.78 HDAC1 (0.55) HDAC1HDAC6CYP19A1CYP11B1CYP11B2
SCHEMBL18577743 0.78 HDAC1 (0.58) HDAC1HDAC6ALDH1A1KDM4E
SCHEMBL28270626 0.77 CYP19A1 (0.47) HDAC1HDAC6CYP19A1CYP11B1CYP11B2
SCHEMBL28868948 0.77 CYP19A1 (0.47) HDAC1HDAC6CYP19A1CYP11B1CYP11B2
SCHEMBL28265365 0.77 CYP19A1 (0.47) HDAC1HDAC6CYP19A1CYP11B1CYP11B2
SCHEMBL13412422 0.77 CYP11B1 (0.49) HDAC1HDAC6CYP19A1CYP11B1CYP11B2
SCHEMBL18029763 0.77 CYP19A1 (0.47) HDAC1HDAC6CYP19A1CYP11B1CYP11B2
SCHEMBL2360983 0.77 CYP19A1 (0.47) HDAC1HDAC6CYP19A1CYP11B1CYP11B2
SCHEMBL8560818 0.77 CYP19A1 (0.47) HDAC1HDAC6CYP19A1CYP11B1CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4709725-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF Progentos Therapeutics, Inc. (US) 2026-03-18 EP disclosed
WO-2024233642-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF PROGENTOS THERAPEUTICS, INC. (US) 2024-11-14 WO disclosed
EP-2964626-A1 ANTIVIRAL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2016-01-13 EP disclosed
US-20160002180-A1 ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (US) 2016-01-07 US disclosed
US-20160002180-A1 ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (US) 2016-01-07 US disclosed
US-20160002180-A1 ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (US) 2016-01-07 US disclosed
WO-2014135472-A1 ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2014-09-12 WO disclosed
WO-2014135472-A1 ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2014-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160002180-A1 ANTIVIRAL COMPOUNDS HAVCR2, EIF2AK2, MAVS HDAC1 428/4885HDAC6 112/4885CYP19A1 1384/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.